KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Biomarin Pharmaceutical (BMRN) Gross Profit (2017 - 2025)

Historic Gross Profit for Biomarin Pharmaceutical (BMRN) over the last 16 years, with Q3 2025 value amounting to $636.0 million.

  • Biomarin Pharmaceutical's Gross Profit rose 1413.38% to $636.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $2.5 billion, marking a year-over-year increase of 1590.88%. This contributed to the annual value of $2.3 billion for FY2024, which is 2048.13% up from last year.
  • Per Biomarin Pharmaceutical's latest filing, its Gross Profit stood at $636.0 million for Q3 2025, which was up 1413.38% from $675.3 million recorded in Q2 2025.
  • Biomarin Pharmaceutical's 5-year Gross Profit high stood at $675.3 million for Q2 2025, and its period low was $305.2 million during Q3 2021.
  • In the last 5 years, Biomarin Pharmaceutical's Gross Profit had a median value of $460.9 million in 2023 and averaged $475.5 million.
  • Its Gross Profit has fluctuated over the past 5 years, first tumbled by 635.56% in 2021, then soared by 3002.94% in 2023.
  • Biomarin Pharmaceutical's Gross Profit (Quarter) stood at $330.1 million in 2021, then grew by 18.43% to $390.9 million in 2022, then surged by 30.03% to $508.3 million in 2023, then rose by 20.24% to $611.2 million in 2024, then grew by 4.07% to $636.0 million in 2025.
  • Its last three reported values are $636.0 million in Q3 2025, $675.3 million for Q2 2025, and $593.6 million during Q1 2025.